Long‐Term Electrical Inhibition of Deep Brain Targets in Movement Disorders
Identifieur interne : 000B12 ( Istex/Curation ); précédent : 000B11; suivant : 000B13Long‐Term Electrical Inhibition of Deep Brain Targets in Movement Disorders
Auteurs : A. L. Benabid [France] ; A. Benazzouz [France] ; D. Hoffmann [France] ; P. Limousin [France] ; P. Krack [France] ; P. Pollak [France]Source :
- Movement Disorders [ 0885-3185 ] ; 1998.
English descriptors
Abstract
Stimulation of the thalamic nucleus ventralis intermedius (Vim) at high (130‐Hz) frequency has been used over the last 8 years as a treatment in 134 patients with movement disorders (91 Parkinson's disease [PD], 23 essential tremor [ET], 21 various dyskinesias and dystonias, including four multiple sclerosis [MS]), implanted with long‐term electrodes connected to a programable stimulator. In PD patients, tremor was selectively suppressed for ≤11 years. In ET patients, results were satisfactory, but in 35% of the cases deteriorated with time, when tremor had an action component. Other types of dyskinesias were much less influenced. Sixty‐eight patients were bilaterally implanted, and 14 were implanted contralateral to a previous thalamotomy. Side effects were often minor, well tolerated, and immediately reversible. Three secondary scalp infections led to temporary removal of implanted material. There was no permanent morbidity. Long‐term Vim stimulation, which is reversible, adaptable, and well tolerated, even by bilaterally operated‐on (68 of 134) and by elderly patients, should replace thalamotomy in the regular surgical treatment of parkinsonian and essential tremors. More recently, we stimulated the subthalamic nucleus (STN) in 51 patients (44 bilateral) and the globus pallidus internus (GPi) in 12 patients (seven bilateral). STN stimulation has a spectacular effect on akinesia and rigidity and may improve the patients so as to maintain them all day at a level similar to their best “on” periods. A 30–50% reduction in drug dosage was possible in most of the patients. GPi stimulation has indications and effects similar to those of pallidectomy: abnormal involuntary movements are totally suppressed, whereas effects on akinesia and rigidity are not so important as they are with STN stimulation. For all three targets, morbidity is low and reversible, even when bilateral implantations are performed. The deep‐brain stimulation method has now proved its safety as compared with ablative surgery and is able to provide a significant improvement to these severely disabled patients. Long‐term follow up is establishing the security of the method, which should be considered in earlier stages of the disease actively to participate to rehabilitation.
Url:
DOI: 10.1002/mds.870131321
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B12
Links to Exploration step
ISTEX:615939659EA3F3C4AFF5DB659B77F9DBBF08F150Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long‐Term Electrical Inhibition of Deep Brain Targets in Movement Disorders</title><author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A. L." last="Benabid">A. L. Benabid</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Benazzouz, A" sort="Benazzouz, A" uniqKey="Benazzouz A" first="A." last="Benazzouz">A. Benazzouz</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Hoffmann, D" sort="Hoffmann, D" uniqKey="Hoffmann D" first="D." last="Hoffmann">D. Hoffmann</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P." last="Limousin">P. Limousin</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Krack, P" sort="Krack, P" uniqKey="Krack P" first="P." last="Krack">P. Krack</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:615939659EA3F3C4AFF5DB659B77F9DBBF08F150</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870131321</idno><idno type="url">https://api.istex.fr/document/615939659EA3F3C4AFF5DB659B77F9DBBF08F150/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B12</idno><idno type="wicri:Area/Istex/Curation">000B12</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Long‐Term Electrical Inhibition of Deep Brain Targets in Movement Disorders</title><author><name sortKey="Benabid, A L" sort="Benabid, A L" uniqKey="Benabid A" first="A. L." last="Benabid">A. L. Benabid</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Benazzouz, A" sort="Benazzouz, A" uniqKey="Benazzouz A" first="A." last="Benazzouz">A. Benazzouz</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Hoffmann, D" sort="Hoffmann, D" uniqKey="Hoffmann D" first="D." last="Hoffmann">D. Hoffmann</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Limousin, P" sort="Limousin, P" uniqKey="Limousin P" first="P." last="Limousin">P. Limousin</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Krack, P" sort="Krack, P" uniqKey="Krack P" first="P." last="Krack">P. Krack</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author><author><name sortKey="Pollak, P" sort="Pollak, P" uniqKey="Pollak P" first="P." last="Pollak">P. Pollak</name><affiliation wicri:level="1"><mods:affiliation>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical and Biological Neurosciences, INSERM Preclinical Neurobiology, Joseph Fourier University of Grenoble, Hǒpital A. Michallon, Grenoble</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998">1998</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">S3</biblScope><biblScope unit="page" from="119">119</biblScope><biblScope unit="page" to="125">125</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">615939659EA3F3C4AFF5DB659B77F9DBBF08F150</idno><idno type="DOI">10.1002/mds.870131321</idno><idno type="ArticleID">MDS870131321</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Deep‐brain stimulation</term><term>Essential tremor</term><term>Parkinson's disease</term><term>Stereotaxy</term><term>Tremor</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="fr">Stimulation of the thalamic nucleus ventralis intermedius (Vim) at high (130‐Hz) frequency has been used over the last 8 years as a treatment in 134 patients with movement disorders (91 Parkinson's disease [PD], 23 essential tremor [ET], 21 various dyskinesias and dystonias, including four multiple sclerosis [MS]), implanted with long‐term electrodes connected to a programable stimulator. In PD patients, tremor was selectively suppressed for ≤11 years. In ET patients, results were satisfactory, but in 35% of the cases deteriorated with time, when tremor had an action component. Other types of dyskinesias were much less influenced. Sixty‐eight patients were bilaterally implanted, and 14 were implanted contralateral to a previous thalamotomy. Side effects were often minor, well tolerated, and immediately reversible. Three secondary scalp infections led to temporary removal of implanted material. There was no permanent morbidity. Long‐term Vim stimulation, which is reversible, adaptable, and well tolerated, even by bilaterally operated‐on (68 of 134) and by elderly patients, should replace thalamotomy in the regular surgical treatment of parkinsonian and essential tremors. More recently, we stimulated the subthalamic nucleus (STN) in 51 patients (44 bilateral) and the globus pallidus internus (GPi) in 12 patients (seven bilateral). STN stimulation has a spectacular effect on akinesia and rigidity and may improve the patients so as to maintain them all day at a level similar to their best “on” periods. A 30–50% reduction in drug dosage was possible in most of the patients. GPi stimulation has indications and effects similar to those of pallidectomy: abnormal involuntary movements are totally suppressed, whereas effects on akinesia and rigidity are not so important as they are with STN stimulation. For all three targets, morbidity is low and reversible, even when bilateral implantations are performed. The deep‐brain stimulation method has now proved its safety as compared with ablative surgery and is able to provide a significant improvement to these severely disabled patients. Long‐term follow up is establishing the security of the method, which should be considered in earlier stages of the disease actively to participate to rehabilitation.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B12 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000B12 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:615939659EA3F3C4AFF5DB659B77F9DBBF08F150
|texte= Long‐Term Electrical Inhibition of Deep Brain Targets in Movement Disorders
}}
| This area was generated with Dilib version V0.6.23. |  |